DWTX — Dogwood Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $10.57m
- -$4.28m
Annual income statement for Dogwood Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 10 | 15.6 | 12.3 | 5.45 | 12.2 |
| Operating Profit | -10 | -15.6 | -12.3 | -5.45 | -12.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -10.3 | -16 | -12.2 | -5.3 | -12.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -10.3 | -16 | -12.2 | -5.3 | -12.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -10.3 | -16 | -12.2 | -5.3 | -12.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -10.3 | -16 | -12.2 | -5.3 | -12.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -31.1 | -47.9 | -27.7 | -7.05 | -12.5 |